Insulin Degludec Injection, Solution
NDC Package 73070-403-15

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Insulin Degludec injection is insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk Pharma, Inc., this product is identified by NDC 73070-403 and is authorized under FDA application BLA203314.

Identification & Billing

NDC Package Code
73070-403-15
Package Description
5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC
Product Code
73070-403
11-Digit Billing Format
73070040315
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.

Clinical Specifications

Proprietary Name
Insulin Degludec
Non-Proprietary Name
Insulin Degludec
Substance Name
Insulin Degludec
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
INSULIN DEGLUDEC 100 U/mL
Pharmacologic Class
Usage Information
Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

Regulatory & Marketing

Labeler Name
Novo Nordisk Pharma, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA203314
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
07-01-2022
End Marketing Date
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73070-403-15 identifies a specific commercial package of 5 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic of Insulin Degludec, a human prescription drug labeled by Novo Nordisk Pharma, Inc.. This injection, solution is formulated for subcutaneous use and contains insulin degludec as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk Pharma, Inc. on July 01, 2022.

What are the primary indications for this medication?

Insulin degludec is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin degludec is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin degludec may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs.

How is this Novo Nordisk Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73070040315. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73070-403-15
11-Digit CMS (5-4-2)
73070-0403-15

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.